6.34
+1.28%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alphamab Oncology
Its shares trade on HKEX under the ticker 9966.HK. It has been listed since 12 December 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥643.2m and a net loss of CN¥129.4m. At that date it held total assets of CN¥2.45bn and shareholders' equity of CN¥2.00bn.
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Dec 2019
- Employees
- 437
- Website
- alphamabonc.com/en ↗
Leadership
Pay as last reported
- Dr. Ting XuExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥6.7m
- Ms. Yang LiuVice President - Corporate Operations, Executive Director, since 2018CN¥3.0m
- Mr. Jing HanChief Commercial Officer
- Ms. Lok Yee ChanJoint Company Secretary
- Ms. Qiulan ChengJoint Company Secretary
- Mr. Man ChoNon-Executive Director
- Mr. Yu Min QiuNon-Executive Director
- Dr. Zijian GuoNon-Executive Independent DirectorCN¥121,000
- Mr. Cheng WeiNon-Executive Independent DirectorCN¥290,000
- Mr. Dong WuNon-Executive Independent DirectorCN¥290,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alphamab Oncology's Suzhou headquarters supports biotechnology innovation in China.
- The company's 437 employees drive research and development in tumor immunobiology.
- Alphamab Oncology's full-industry chain focuses on innovative tumor immunobiology drugs.
Weaknesses
- Alphamab Oncology's IPO date of 12 December 2019 may limit recent market expansion.
- The company's domestic and overseas market operations face regulatory challenges.
- Alphamab Oncology's reliance on biotechnology sector may increase vulnerability to industry downturns.
Opportunities
- Alphamab Oncology can expand its protein engineering platform for new drug development.
- The firm's antibody screening platform offers potential for international collaboration.
- Growing demand for innovative tumor immunobiology drugs presents market opportunities.
Threats
- Alphamab Oncology faces competition from other biotechnology firms in China.
- Regulatory changes in the Health Care sector could impact drug approvals.
- Economic downturns may reduce investment in biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.